Literature DB >> 1709151

Evaluation of fludarabine phosphate in malignant melanoma. A Southwest Oncology Group study.

J A Kish1, K Kopecky, M K Samson, D D Von Hoff, W S Fletcher, R A Kempf, F M Muggia.   

Abstract

Twenty-seven evaluable patients with advanced malignant melanoma received fludarabine phosphate in a daily x 5 injection. Initial dosing was based on the presence of previous radiation therapy. There was no response seen in these patients despite appropriate dose escalation. Myelosuppression occurred without significant sequelae.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1709151     DOI： 10.1007/bf00194559

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  3 in total

1.  Enhancement of 9-beta-d-arabinofuranosyladenine cytotoxicity to mouse leukemia L1210 in vitro by 2'-deoxycoformycin.

Authors:  C E Cass; T H Au-Yeung
Journal:  Cancer Res       Date:  1976-04       Impact factor: 12.701

2.  Combination phase 1-II study of imidazole carboxamide (NCS45388).

Authors:  D E Wagner; G Ramirez; A J Weiss; G Hill
Journal:  Oncology       Date:  1972       Impact factor: 2.935

3.  Phase I clinical trial of fludarabine phosphate (F-ara-AMP).

Authors:  E S Casper; A Mittelman; D Kelson; C W Young
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333
  3 in total
  6 in total

1.  Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.

Authors:  Smita S Chandran; Robert P T Somerville; James C Yang; Richard M Sherry; Christopher A Klebanoff; Stephanie L Goff; John R Wunderlich; David N Danforth; Daniel Zlott; Biman C Paria; Arvind C Sabesan; Abhishek K Srivastava; Liqiang Xi; Trinh H Pham; Mark Raffeld; Donald E White; Mary Ann Toomey; Steven A Rosenberg; Udai S Kammula
Journal:  Lancet Oncol       Date:  2017-04-07       Impact factor: 41.316

2.  Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma.

Authors:  Steven A Rosenberg; James C Yang; Paul F Robbins; John R Wunderlich; Patrick Hwu; Richard M Sherry; Douglas J Schwartzentruber; Suzanne L Topalian; Nicholas P Restifo; Armando Filie; Richard Chang; Mark E Dudley
Journal:  J Immunother       Date:  2003 Sep-Oct       Impact factor: 4.456

Review 3.  Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.

Authors:  S R Ross; D McTavish; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

4.  Phase II trial of carbetimer in metastatic melanoma.

Authors:  W D Quan; M S Mitchell
Journal:  Invest New Drugs       Date:  1993 May-Aug       Impact factor: 3.850

Review 5.  Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma.

Authors:  G Rodriguez
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

6.  Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma.

Authors:  Herschel Wallen; John A Thompson; J Zachary Reilly; Rebecca M Rodmyre; Jianhong Cao; Cassian Yee
Journal:  PLoS One       Date:  2009-03-09       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.